News

Cornell’s network of business incubators and accelerators have developed into a growing and robust entrepreneurial engine nurtured with resources, training and mentorship that help faculty, research staff and graduate students launch marketable ideas and technologies.

Dr. Shahin Rafii, director of the Ansary Stem Cell Institute and chief of the Division of Regenerative Medicine at Weill Cornell Medicine, has received an Outstanding Investigator Award (R35) from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH), for an ambitious project to accelerate regenerative medicine technology.

Researchers from Weill Cornell Medicine, Cornell University and San Jose State University have identified six free planning models for estimating hospital capacity requirements when COVID-19 cases surge.

Human organoids, tiny organ-like structures grown in the laboratory, can be used to identify potential COVID-19 drugs in an automated, high-throughput fashion.

Weill Cornell Medicine and NewYork-Presbyterian investigators have built a machine-learning tool that can predict SARS-CoV-2 infection based on age, gender, race and 27 routine laboratory test results.

T-cells taken from the blood of people who recovered from a COVID-19 infection can be successfully multiplied in the lab and maintain the ability to effectively target proteins that are key to the virus’s function.

When a patient is hospitalized with COVID-19, signs of damage to the right side of the heart may indicate a greater risk of death, according to a study from investigators at Weill Cornell Medicine and NewYork-Presbyterian.

Dr. Augustine M.K. Choi, the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and provost for medical affairs of Cornell University, has been elected to the National Academy of Medicine.

Physicians who care for the most socially disadvantaged patients were more likely to receive lower scores in a Centers for Medicare & Medicaid Services (CMS) program that financially rewards high-value care than physicians who care for more affluent populations, according to a study by Weill Cornell Medicine researchers.

Cancer patients who contracted COVID-19 during the height of the pandemic in New York City had similar outcomes to other patients with COVID-19.

Drawing on New York’s diverse population, Weill Cornell Medicine scientists have been awarded grants from the New York Genome Center (NYGC) to study how several types of cancer differ in patients with different genetic backgrounds and point to precision treatments for groups that have been historically underrepresented in cancer research. 

An intercampus research team at Weill Cornell Medicine and Cornell’s Ithaca campus has been awarded a five-year, $3.65 million grant from the National Institutes of Health (NIH) to develop a quick, inexpensive method for accurately diagnosing urinary tract infections in kidney transplant patients by carrying out molecular profiling of cell-free DNA in urine.

A long-standing debate among cardiologists comparing two common heart procedures is closer to being resolved.

The amount of SARS-CoV-2 virus, or “viral load,” in cancer patients and in the general inpatient population upon hospital admission may predict their risk of dying of the infection, according to a study led by researchers at Weill Cornell Medicine and NewYork-Presbyterian.

With the need for wide scale COVID-19 testing to allow societies reopen safely, a group from Weill Cornell Medicine and other academic medical centers and research organizations have announced the launch of a global competition for low-cost, high-quality and scalable COVID-19 tests, called the COVID-19 XPRIZE, in a letter published Aug. 20 in Nature Biotechnology.

A study by investigators at Weill Cornell Medicine and NewYork-Presbyterian aims to answer one of COVID-19’s biggest mysteries: why do some people become severely ill, while others have no symptoms?

Dr. Anna S. Nam, an assistant professor of pathology and laboratory medicine at Weill Cornell Medicine, has received a 2020 Early Independence Award from the National Institutes of Health’s (NIH) High Risk, High Reward Research program and a 2020 Burroughs Wellcome Fund Career Award for Medical Scientists. 

Cancer cells rearrange, copy, and delete their DNA in complex but distinct patterns, according to new research from a multi-institution team led by investigators at Weill Cornell Medicine and the New York Genome Center. The investigators developed sophisticated new algorithms to analyze nearly 3,000 genome sequences from human tumors.

Neurological complications ranging from headache, malaise and loss of smell to confusion and disabling strokes have been a disturbing consequence of COVID-19.

Weill Cornell Medicine investigators have received a total of $3.5 million from the Patient-Centered Outcomes Research Institute (PCORI) to study the effectiveness of telehealth services during the COVID-19 pandemic, and to develop models that can aid in clinical decision making in the treatment of the virus.